Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Consolidated Statements of Operations and Comprehensive Loss [Abstract]
Grant revenue	$ 288,000		$ 319,000
Operating expenses
Research and development	4,066,000	$ 3,019,000	9,464,000	$ 8,156,000
General and administrative	1,845,000	3,758,000	5,989,000	7,220,000
Total operating expenses	5,911,000	6,777,000	15,453,000	15,376,000
Loss from operations	(5,623,000)	(6,777,000)	(15,134,000)	(15,376,000)
Other income (expense)
Interest income	4,000	13,000	28,000	89,000
Interest expense	(150,000)	(190,000)	(451,000)	(726,000)
Other income (expense)		(1,000)		3,000
Change in fair value of derivative liabilities				1,117,000
Total other income (expense), net	(146,000)	(178,000)	(423,000)	483,000
Net loss	$ (5,769,000)	$ (6,955,000)	$ (15,557,000)	$ (14,893,000)
Per share information:
Net loss per share, basic	$ (0.31)	$ (0.73)	$ (0.99)	$ (2.05)
Weighted average shares outstanding, basic	18,394,614	9,552,688	15,740,858	7,254,803
Net loss per share, diluted	$ (0.31)	$ (0.73)	$ (0.99)	$ (2.11)
Weighted average shares outstanding, diluted	18,394,614	9,552,688	15,740,858	7,497,194